Recommendations for Tumor Mutational Burden Assay Validation and Reporting-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recommendations for Tumor Mutational Burden Assay Validation and Reporting

Published:2024-08 Issue:8 Volume:26 Page:653-668
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Furtado Larissa V.^ORCID,Bifulco Carlo,Dolderer Daniel^ORCID,Hsiao Susan J.^ORCID,Kipp Benjamin R.,Lindeman Neal I.,Ritterhouse Lauren L.,Temple-Smolkin Robyn L.^ORCID,Zehir Ahmet,Nowak Jonathan A.

Funder

Association for Molecular Pathology

Publisher

Elsevier BV

Reference60 articles.

1. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges;Fancello;J Immunother Cancer,2019

2. FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients;Wang;Front Oncol,2021

3. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics;Twomey;AAPS J,2021

4. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors;Marcus;Clin Cancer Res,2019

5. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors;Marcus;Clin Cancer Res,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP